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Abstract: Background: Little is known about the impact of frailty on length of stay (LOS), cost and
in-hospital procedural outcomes of cardiac implantable electronic device (CIED)
implantation procedures.
Methods: All de novo CIED implantations recorded in the United States (2004-2014)
from a national database were stratified according to the Hospital Frailty Risk Score
into low-risk (LRF;<5), intermediate-risk (IRF;5-15) and high-risk (HRF;>15) frailty
groups. Regression analyses were performed to assess the association between frailty
and procedural outcomes.
Results: Out of 2,902,721 implantations, LRF, IRF and HRF were 77.6%, 21.2% and
1.2%, respectively. Frailty increased from 2004 to 2014 (IRF: 14.3% to 32.5%, HRF:
0.2% to 3.3%). Complications were 2-3 fold higher in the IRF and HRF groups, while
all-cause mortality was 4 to 9-fold higher in IRF (2.9%) and HRF (5.3%) groups,
depending on the type of CIED (p<0.001for all). Rates of complications increased over
the study years and all-cause mortality declined, especially in the higher frailty risk
groups (2004 vs. 2014;Mortality: IRF:3.8 vs. 2.2%, HRF:9.9 vs. 4.5%;Bleeding: IRF:3.7
vs. 9.0%, HRF:3.9 vs. 12.2%;Thoracic: IRF:4.3 vs. 6.0%, HRF:2.9 vs. 9.1%;Cardiac:
IRF:0.5 vs. 0.9%, HRF:0.5 vs. 0.9%). Rising frailty was associated with increase in cost
(p<0.001) and LOS (median 3, 8, 11 days for LRF, IRF, HRF respectively, p<0.001).
The cost for HRF patients receiving a defibrillator was approximately quarter million US
dollars per patient.
Conclusion: Frailty is associated with worse clinical outcomes, higher cost and LOS
independent of age or CIED type. Our findings emphasize the importance of frailty
assessment.
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Background: Little is known about the impact of frailty on length of stay (LOS), cost and in-
hospital procedural outcomes of cardiac implantable electronic device (CIED) implantation 
procedures. 
 
Methods: All de novo CIED implantations recorded in the United States (2004-2014) from a 
national database were stratified according to the Hospital Frailty Risk Score into low-risk 
(LRF;<5), intermediate-risk (IRF;5-15) and high-risk (HRF;>15) frailty groups. Regression 
analyses were performed to assess the association between frailty and procedural outcomes. 
 
Results: Out of 2,902,721 implantations, LRF, IRF and HRF were 77.6%, 21.2% and 1.2%, 
respectively. Frailty increased from 2004 to 2014 (IRF: 14.3% to 32.5%, HRF: 0.2% to 3.3%). 
Complications were 2-3 fold higher in the IRF and HRF groups, while all-cause mortality was 
4 to 9-fold higher in IRF (2.9%) and HRF (5.3%) groups, depending on the type of CIED 
(p<0.001for all). Rates of complications increased over the study years and all-cause mortality 
declined, especially in the higher frailty risk groups (2004 vs. 2014;Mortality: IRF:3.8 vs. 
2.2%, HRF:9.9 vs. 4.5%;Bleeding: IRF:3.7 vs. 9.0%, HRF:3.9 vs. 12.2%;Thoracic: IRF:4.3 vs. 
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associated with increase in cost (p<0.001) and LOS (median 3, 8, 11 days for LRF, IRF, HRF 
respectively, p<0.001). The cost for HRF patients receiving a defibrillator was approximately 
quarter million US dollars per patient. 
 
Conclusion: Frailty is associated with worse clinical outcomes, higher cost and LOS 
independent of age or CIED type. Our findings emphasize the importance of frailty assessment. 
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Background: Little is known about the impact of frailty on length of stay (LOS), cost and in-
hospital procedural outcomes of cardiac implantable electronic device (CIED) implantation 
procedures. 
 
Methods: All de novo CIED implantations recorded in the United States (2004-2014) from a 
national database were stratified according to the Hospital Frailty Risk Score into low-risk 
(LRF;<5), intermediate-risk (IRF;5-15) and high-risk (HRF;>15) frailty groups. Regression 
analyses were performed to assess the association between frailty and procedural outcomes. 
 
Results: Out of 2,902,721 implantations, LRF, IRF and HRF were 77.6%, 21.2% and 1.2%, 
respectively. Frailty increased from 2004 to 2014 (IRF: 14.3% to 32.5%, HRF: 0.2% to 3.3%). 
Complications were 2-3 fold higher in the IRF and HRF groups, while all-cause mortality was 
4 to 9-fold higher in IRF (2.9%) and HRF (5.3%) groups, depending on the type of CIED 
(p<0.001for all). Rates of complications increased over the study years and all-cause mortality 
declined, especially in the higher frailty risk groups (2004 vs. 2014;Mortality: IRF:3.8 vs. 
2.2%, HRF:9.9 vs. 4.5%;Bleeding: IRF:3.7 vs. 9.0%, HRF:3.9 vs. 12.2%;Thoracic: IRF:4.3 vs. 
6.0%, HRF:2.9 vs. 9.1%;Cardiac: IRF:0.5 vs. 0.9%, HRF:0.5 vs. 0.9%). Rising frailty was 
associated with increase in cost (p<0.001) and LOS (median 3, 8, 11 days for LRF, IRF, HRF 
respectively, p<0.001). The cost for HRF patients receiving a defibrillator was approximately 
quarter million US dollars per patient. 
 
Conclusion: Frailty is associated with worse clinical outcomes, higher cost and LOS 
independent of age or CIED type. Our findings emphasize the importance of frailty assessment. 
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The effect of frailty on clinical outcomes of patients undergoing CIED implantations remains 
unknown. In this study, we show that the prevalence of frailty has increased from 2004 to 2014 
and that patients with intermediate and high-risk frailty are associated with higher mortality 
and worse procedure-related complications after CIED implantations. Our findings emphasize 
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the importance of incorporating frailty assessment into routine clinical practice when assessing 
patients undergoing CIED implantations. 
Introduction 
The association between frailty and cardiovascular outcomes has become increasingly 
recognized in recent years. 1 2, 3 Frailty is defined as “a clinically recognizable state of 
increased vulnerability resulting from aging-associated decline in reserve and function across 
multiple physiologic systems such that the ability to cope with everyday or acute stressors is 
compromised”. 4 Although frailty is synonymously used with ageing and multimorbidity in 
clinical practice, not all frail individuals suffer from chronic conditions or advanced age.5, 6 
Several studies have demonstrated that young patients with chronic illnesses and 
multimorbidity are also considered ‘biologically frail’ 7, and up to 7% of frail individuals have 
no common chronic conditions, while 25% of frail individuals have only one chronic 
condition.5  
Cardiac implantable electronic devices (CIED), including permanent pacemakers 
(PPM) and implantable cardioverter-defibrillators (ICD), are important in the management of 
serious rhythm abnormalities. CIEDs also include cardiac resynchronization therapy with 
pacemaker alone (CRT-P) or with defibrillator (CRT-D) that play an important role in the 
management of patients with advanced heart failure refractory to optimal medical therapy. 8-
10 The prevalence and clinical outcomes of frail patients undergoing CIED implantation has 
not been previously studied nationally as these patients are frequently excluded from 
randomized trials. Consequently, little is known about the effect of frailty on clinical outcomes, 
and whether these outcomes differ according to the type of CIED implanted. Few studies have 
looked at the prevalence or associated outcomes of frailty in cardiac devices, [3, 21, 22] but 
these have been limited by their analyses of specific types of CIED procedures (e.g. ICD) in 
patients with certain indications (e.g. primary prevention) or in highly specialized centers, 
rendering their findings as poorly representative of the background population of CIED 
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implantations.  In addition, the majority of studies investigating cardiovascular outcomes in 
frail patients had only included elderly patients2, 3, 11 while excluding younger and comorbid 
patients who may be biologically frail 7.  
 While numerous frailty scores exist, no single score is considered a gold standard.12 
The majority of scores require clinical evaluation of patients, which is often challenging and 
time-consuming in the acute setting, and cannot be computed from administrative datasets. The 
Hospital Frailty Risk Score (HFRS) was recently introduced as a means to score frailty from 
administrative data 13 and was validated against two prominent scores: Fried Frailty Phenotype 
and Rockwood Frailty Index. In the present study we utilized the HFRS to study trends in 
frailty in the United States over a ten-year period and examine its effect on clinical outcomes 




The National Inpatient Sample (NIS) is the largest publicly available all-payer database 
of hospitalized patients in the United States and is sponsored by the Agency for Healthcare 
Research and Quality as a part of the Healthcare Cost and Utilization Project (HCUP). 14 
Further information on its structure and validation is available in the supplements (Appendix 
A) 
Study Design and Population 
All hospitalizations during which de novo CIED implantations were performed were 
retrospectively analyzed.  CIED procedures (PPM, CRT-P, CRT-D, and ICD), patient 
characteristics, comorbidities, and clinical outcomes were extracted from NIS using the 
International Classification of Diseases, ninth revision (ICD-9) procedure and diagnosis codes 
provided in the supplements (Table S1). Furthermore, using ICD-9 equivalents of the ICD-10 
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codes that make up HFRS, each patient was assigned a score and stratified into one of three 
risk groups; Low-Risk Frailty (LRF; <5), Intermediate-Risk Frailty (IRF; 5-15) and High-Risk 
Frailty (HRF; >15) (Table S2). Missing records (n=18,321, 3% of dataset) for age, gender, 
admission or discharge date, length of stay and mortality were excluded from the analysis, as 
were any cases of device upgrades or generator replacements. A flow diagram illustrating the 
selection process and missing variable in the present study is presented in the supplements 
(Figure S1).   
Procedural data and clinical outcomes other than in-hospital all-cause mortality, length 
of stay and total charges were extracted using the relevant ICD-9 and Clinical Classification 
Software (CCS) diagnosis and procedure codes (see supplements - Table S1); procedure-
related bleeding, cardiac complications and thoracic complications.  
Outcomes 
The primary outcome measures were in-hospital rates of all-cause mortality, major 
acute cardiovascular events (MACE), and procedural-related complications (bleeding, thoracic 
and cardiac complications) between frailty risk groups according to type of CIED implanted. 
In-hospital MACE was defined as a composite of all-cause mortality, thoracic and cardiac 
complications, device-related infection and reoperation. Procedure-related bleeding was 
defined as any post-procedural hemorrhage according to ICD-9 diagnosis codes specified in 
the supplements (Table S1). Thoracic complications were defined as a composite of acute 
pneumothorax or hemothorax, with or without drainage, or thoracic vascular injury, while 
cardiac complications were defined as a composite of cardiac tamponade, hemopericardium, 
pericardiocentesis.  
The secondary outcome was to evaluate the economic burden of CIED implantations 
in patients with intermediate and high risk of frailty compared to those with a low risk of frailty 
as measured by length of stay and total hospitalization charges, measured in US Dollars (USD). 
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Statistical Analysis 
Statistical analysis was performed using SPSS version 24 (IBM Corp, Armonk, NY). 
Continuous variables are presented as medians with interquartile range (IQR) and were 
compared using the Kruskal-Wallis test. Categorical variables are presented as percentages and 
were analyzed using the chi-squared (X2) test.  
Multivariable logistic regression models were fitted using maximum likelihood 
estimation to examine the association of frailty with each in-hospital outcome (all-cause 
mortality and individual complications) using low-risk frailty as the reference category in the 
form of odds ratios (aOR), and adjusting for all covariates that were not part of the HFRS as 
mentioned in the supplements (Appendix B). The model fits were assessed using the Hosmer-
Lemeshow statistic, 15 and all models were able to correctly classify at least 97% of those who 
experienced the outcome being assessed. 
A sensitivity analysis of clinical outcomes stratified by patient age (greater or less than 
75 years) was conducted to ensure that these outcomes were not drastically different in younger 
patients.  
Results 
A total of 2,902,721 hospitalizations were recorded during which patients underwent 
de novo CIED implantation in the United States between 2004 and 2014. The proportion of 
patients in the low, intermediate and high frailty risk groups were 77.6%, 21.2% and 1.2%, 
respectively. Figure 1a illustrates a rise in prevalence of frailty amongst patients undergoing 
CIED implantation over the study decade, as evidenced by a rise in IRF and HRF groups from 
2004 to 2014 (IRF: 14.3% to 32.5% and HRF: 0.2% to 3.3%). The rising trend of frailty over 
the study years was observed in all types of CIED (Figure 1b). The most common procedure 
in all study groups was PPM insertion, followed by ICD, CRT-D and finally CRT-P (Table 
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S3). There was a shifting trend towards more complex device implantations in HRF patients 
over the study period (Figure 1c).  
Several differences in patient demographics are observed between the frailty risk 
groups of the entire CIED cohort (Table S3, p<0.001 for all). Patients with IRF and HRF were 
generally older and less likely to be male or caucasian, and more likely to have a history of 
arrhythmias such as ventricular fibrillation, atrial fibrillation, and cardiac arrest. Although 
higher frailty risk groups (IRF and HRF) had a higher prevalence of certain cardiovascular risk 
factors such as complicated diabetes, previous cerebrovascular accidents (CVA), hypertension 
and valvular heart disease, they were less likely to have had a history AMI or have undergone 
previous percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).  
The demographic differences between frailty risk groups were also similar in the subgroup 
analyses of individual devices (PPM, CRT-P, CRT-D and ICD; Tables S4-S6).  
 
In-hospital adverse outcomes 
The overall rates of MACE and all-cause mortality were 5% and 1%, respectively, with 
a frequency of procedure-related complications (thoracic and cardiac complications, and 
bleeding) varying between 0.4% and 3% (Table 1, Figure 2). 
 The unadjusted rates of all-cause mortality, thoracic and cardiac complications, and 
procedure-related bleeding were significantly higher in the IRF and HRF groups compared to 
the LRF group in the entire CIED cohort (IRF and HRF vs. LRF; all-cause mortality: 2.9% and 
5.3% vs. 0.4%, thoracic: 5.2% and 7.5% vs. 2.3%, cardiac: 0.7% and 0.7% vs. 0.3%, bleeding: 
6.0% and 8.7% vs. 2.0%; p<0.001 for all, Table 1, Figure 2) as well as in each CIED subgroup 
(see supplements - Table S7, Figure 3). The rates of in-hospital MACE increased over the study 
years in all the frailty groups, primarily driven by a rise in the incidence of bleeding and 
thoracic complications, especially in the higher risk frailty groups where these complications 
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increased by two to three folds (IRF and HRF, Figure 4, Table S8). In contrast, all-cause 
mortality has decreased over the study years, particularly in the higher risk groups (IRF and 
HRF, Figure 4, Table S8). 
Device-related infection was more than three-fold higher in IRF and HRF groups 
compared to the LRF group, but there was no statistically significant difference between the 
higher risk groups (IRF vs. HRF: 2.0% vs. 1.9%) (Table 1, Figure 2). The higher risk of device 
related infection in both IRF and HRF groups was consistent across all CIED subtypes 
compared to the LRF group, but was exceptionally higher in frail patients (IRF and HRF) 
undergoing complex device implantation (CRT-D, CRT-P and ICD) compared to those 
undergoing pacemakers (Table S7, Figure 3). The higher frailty groups were more likely to 
undergo pocket revision (IRF:1.5% and HRF: 1.6% vs. LRF 1.0%, p<0.001) but less likely to 
undergo lead revision (IRF:1.5% and HRF: 1.4% vs. LRF 1.6%, p=0.003) compared to the 
lower frailty group. (Table 1).  
 After adjustment for baseline differences, the higher risk of adverse events in the IRF 
and HRF groups persisted in multivariate analysis (Table 2). The overall odds of any 
complication (MACE) was two to three-fold higher in IRF and HRF groups compared to LRF 
group, regardless of the type of implanted device (Table 2, Figure 5). Patients with IRF and 
HRF were significantly associated with higher odds of all-cause mortality in the same 
admission after receiving a CIED (at least 4-fold and 7-fold respectively) compared to those 
with LRF, irrespective of the type of CIED. All-cause mortality was significantly higher in the 
HRF group than the IRF group in most device groups (PPM, CRT-P and ICD), although in 
patients undergoing CRT-D procedures both groups were at a seven-fold increased odds of all-
cause mortality compared to the LRF group (IRF aOR: 6.83 [6.16, 7.58]; HRF aOR: 7.06 [5.41, 
9.21], p<0.001 for both).   
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 The adjusted odds of procedure-related bleeding and other complications (thoracic and 
cardiac) were significantly higher (≥1.5 fold) in patients with IRF and HRF when compared to 
the LRF group (Figure 5), with the exception of cardiac complications in patients undergoing 
CRT-P implantation (4-fold increased odds in IRF and HRF groups) and ICD (insignificant 
odds in HRF patients: aOR 1.12 [0.98,1.21], p=0.07).  
 Frailty was the strongest independent predicter of adverse events in patients undergoing 
CIED implantation, with other independent predictors presented in supplements (Table S9).  
   
Total hospitalization charges and length of stay  
  The median total hospitalization charges for the entire cohort were USD 71,641 (USD 
42,142, USD 120,910), ranging from USD 51,109 (USD 34,352, USD 82,306) for PPM 
procedures to USD 124,613 (USD 91,733, USD 174,779) in CRT-D procedures (see 
supplements - Table S7). Median hospitalization charges were approximately 1.5 and 2-folds 
higher in IRF and HRF groups, respectively, compared to the LRF group, in all CIED subtypes 
(Table S7).  
 The mean length of stay for any CIED implantation procedures was prolonged 
significantly as the frailty risk increased, with IRF and HRF patients experiencing 2-3 folds 
longer admissions, regardless of the type of CIED implanted, compared to LRF patients (Table 
S7).   
Sensitivity Analysis 
A sensitivity analysis of clinical outcomes stratified by patient age (less or greater than 
75 years) was performed (Table S10). The proportion of patients younger than 75 years at the 
time of CIED implantation was 48% (n=1,351,900). At least one in six young patients (<75 
years; 17.4%) was classified as intermediate-risk frailty, and 0.8% of young patients were high-
risk frailty.  
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All adverse events were higher in IRF and HRF groups in both young and old patients 
(Table S6) in line with the findings observed in the entire cohort.  
 
Discussion 
 The present study, drawn from a contemporary cohort of almost 3 million 
hospitalizations in the United States, is the first to report national estimates of the prevalence 
and in-hospital clinical outcomes of de novo CIED implantations according to frailty risk 
groups. We found a rise in the prevalence of frailty amongst patients undergoing CIED with a 
rise in intermediate-risk and high-risk frailty patients from 14.3% to 32.5% and 0.2% to 3.3%, 
respectively between 2004 and 2014. Patients with intermediate and high-risk frailty compared 
to those with low-risk frailty, regardless of the type of CIED implanted and patient age, had 
significantly worse in-hospital outcomes after CIED implantation procedures, including all-
cause mortality, infection, procedure-related bleeding, and thoracic and cardiac complications. 
Finally, we highlight the economic burden of frailty on healthcare facilities where patients 
undergo CIED implantation procedures where the length of stay and hospitalization charges of 
patients with intermediate-risk and high-risk frailty were notably higher than in patients with 
low-risk frailty.  
The present study is the first to examine the prevalence of frailty in an unselected and 
contemporary national cohort of CIED implantations over a decade and shows a significant 
rise in the prevalence of intermediate and high risk frailty patients receiving such procedures 
over the study period. A European Heart Rhythm Association (EHRA) survey recently showed 
that less than 10% of patients undergoing CIED implantations in European centers are 
considered prefrail or frail. 11 However, the definition of frailty and the study findings were 
based on physicians’ own opinions without the use of a standardized assessment tool for frailty.  
Another study by Kramer et al. reported a frailty prevalence of 12.8% amongst patients with 
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CIED’s implanted more than 2 months before prior to attending an ambulatory device clinic in 
a tertiary center in the United States, although their inclusion cohort (n=219) represented less 
than half of patients who attended their ambulatory device clinic (n=448).16  
Our findings suggest worse clinical outcomes and higher all-cause mortality in frail 
patients undergoing CIED implantations, regardless of the type of CIED they receive, and of 
their age. In-hospital mortality all-cause in patients with intermediate and high-risk frailty was 
five to nine-fold higher than in low-risk frailty patients, depending on the type of CIED 
implanted, while other complications were between 50% and 150% more likely to occur in 
intermediate and high risk frailty patients in the total CIED cohort. Furthermore, we observe a 
rise in the incidence of procedure-related complications and a decline in all-cause mortality 
over the study years, especially in patients with higher-risk frailty. The observed upward trend 
in complications is in line with more complex device implantations, while the decline in in 
mortality is likely due to advancements in specialized geriatric care provided to more frail 
patients or better case selection.17 A study of Medicare patients with heart failure undergoing 
primary prevention ICD implantation between 2006 and 2009 reported significantly higher 
one-year mortality in frail patients compared to those without any medical  conditions other 
than heart failure (22% vs. 4%).3 Although their analysis provided insight in to the outcomes 
of this specific population, it was derived from decade-old data and was not representative of 
contemporary older age ICD populations. Similarly, an analysis of CIED implantations 
between 1997 and 2004 in the United States reported higher in-hospital mortality and all-cause 
complications in patients who were classified as frail according to the authors’ own definitions, 
indicated by advanced age, comorbidity burden and emergency admission. 18 Our analysis 
suggests that frailty is associated with adverse outcomes irrespective of the CIED device 
implanted, with similar risk of adverse outcomes associated with both defibrillator (ICD and 
CRT-D) and non-defibrillator (PPM and CRT-P) devices in frail patients. These findings could 
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be relevant to cardiologists when deciding on the type of device in frail patients who may 
otherwise be eligible for a defibrillator therapy, and whom are currently much less likely to 
receive a defibrillator device according to a recent EHRA survey.11 An interesting finding in 
our subgroup analysis is the higher rate of in-hospital all-cause mortality in patients undergoing 
PPM and CRT-P implantations, which probably demonstrates cardiologists’ selection of 
patients who are more likely to benefit from more complex device implantation.   
There was a significant disparity in rates of device-related infection between frailty 
groups as well as between different CIED subtypes. Higher frailty groups were more likely to 
experience such a complication compared to the low frailty group, an observation that was 
consistent across all CIED subtypes. Noteworthy, there rates of device-related infection were 
significantly higher in intermediate and high-risk frail patients undergoing complex device 
therapy (CRT-P, CRT-D and ICD; 2.6-5.3%) compared to those undergoing pacemaker 
implantation (1.4%). While the knowledge of procedure-specific information is vital in 
explaining the observed differences, there are several justifications for the higher rates of 
infection in complex device groups, especially in higher risk frailty patients. Complex device 
implantation is often associated with longer procedural time and more prolonged lead 
manipulation, which is known to predispose to more venous damage, secondary inflammation 
and, in turn, infection.19, 20  More frail patients are more susceptible to such processes due to 
their reduced host defense and resistance to infections.21, 22 Our present findings emphasize 
the importance of frailty assessment from an economic perspective since device-related 
infections are associated with significant cost implications.23 We believe that our study 
informs clinicians of more accurate rates of overall complications and the need for repeat 
procedures depending on the patient’s frailty score. For example, patients with a higher risk of 
frailty may be more likely to require pocket revision as demonstrated in our analysis, which is 
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more likely in these patients due to their increased tissue fragility and thinner layer of 
subcutaneous fat.24 
Our study is the first to highlight the economic burden of CIED implantations in frail 
patients. We show that total hospitalization charges of CIED implantation admissions were 
significantly higher (50-100%) in patients with intermediate and high-risk frailty, with an 
incremental rise in costs as the risk of frailty increases. Hospitalizations where high-risk frailty 
patients received CRT-D and ICD devices cost almost a quarter million US dollars per patient. 
This could be possibly attributed to the higher rate of complications in higher risk (intermediate 
and high risk) groups that often require prolonged and more intensive management as 
evidenced by a longer length of stay (two to three folds longer in intermediate and high-risk 
frailty compared to low risk frailty patients). These findings raise questions about the 
sustainability of offering such devices to frail patients, most of which receiving public 
insurance (Medicare and Medicaid), and whether these therapies have an impact on their life 
quality and expectancy in view of their high rates of all-cause mortality. While pre-habilitation 
in patients with frailty has been shown to improve outcomes in patients undergoing some 
procedures25, it is unclear whether targeting frailty in patients that are due to undergo CIED 
implantation electively may contribute to better outcomes. Future studies should consider this 




There are several limitations to our study. First, the administrative nature of the NIS 
database, as with any such database has limitations around the accuracy of coding with no 
external validation. However, the use of ICD-9 codes from such databases has been previously 
validated for the purpose of cardiovascular research 26 Second, since the NIS dataset does not 
provide information on pharmacotherapy, indication for each CIED device (e.g. type of 
arrhythmia and primary vs. secondary prevention in CRT-D and ICD procedures), type of 
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pacemaker (dual chamber versus biventricular pacemaker), operator experience and procedure 
time, we were unable to adjust for the differences in these covariates between the study groups. 
Third, the HFRS was validated in patients over the age of 75, however, our sensitivity analysis 
demonstrated similar outcomes between younger (<75 years) and older (>75 years) patients. 
Fourth, since the majority of elective CIED implantations are performed in the outpatient 
setting, which is not captured in NIS. It is likely that the distribution of frailty and subsequent 
outcomes are different in patients admitted electively but we are unable to demonstrate this 
contrast from the present dataset. Finally, the NIS only reports in-hospital outcomes and so the 
present findings may not be applicable to longer term outcomes although the majority of 
complications have been shown to occur in the peri-procedural and early post procedural phase. 
Conclusion 
  The present nationwide analysis of CIED implantations in the United States shows that 
intermediate-risk and high-risk frailty, as defined by the Hospital Frailty Risk Score, has 
increased significantly over the study decade and has become more common amongst patients 
undergoing these procedures. Frailty is associated with significantly worse post-procedural 
outcomes and higher all-cause mortality in patients undergoing CIED implantation regardless 
of their age. Our findings support the incorporation of an objective frailty risk score into the 
routine risk assessment of patients undergoing such procedures to support shared decision-
making and improve prognostication around their procedural risk and anticipated outcomes.   
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Figure titles and legends 
 




HRF: High-risk frailty; IRF: Intermediate-risk frailty; LRF: Low-risk frailty 
 
Figure 1b. Prevalence of frailty according to type of CIED 
Legend:  
HRF: High-risk frailty; IRF: Intermediate-risk frailty; LRF: Low-risk frailty 
 
Figure 2. In-hospital adverse events of frailty groups in total cohort  
Legend:  
*Comp: complications; p<0.001 for all outcomes; MACE: Composite of mortality, thoracic and cardiac complications, 
device-related infection and reoperation. 
 
Figure 3. In-hospital adverse events in frailty groups according to type of CIED  
Legend:  
*Comp: complications; p<0.001 for all outcomes; ICD: automated implantable cardioverter-defibrillator; CRT-P & CRT-D: 
cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; MACE: Composite of mortality, thoracic and 
cardiac complications, device-related infection and reoperation; PPM: permanent pacemaker. 
 
Figure 4. Trends of in-hospital adverse events according to frailty group (2004-2014)* 
*p<0.001 for all trends except MACE in IRF (p=0.013).  
 
Figure 5. Adjusted relative risk (RR) and 95% confident intervals of adverse outcomes 
according to frailty risk group and type of CIED (reference is low-frailty risk group)  
Legend:  
*p>0.05 (p<0.001 otherwise); **Comp: complications; ICD: automated implantable cardioverter-defibrillator; CRT-P & 
CRT-D: cardiac resynchronization therapy - pacemaker and - defibrillator, respectively; MACE: Composite of mortality, 
thoracic and cardiac complications, device-related infection and reoperation; PPM: permanent pacemaker; models adjusted 
for: age, sex, weekend admission, primary expected payer, median household income, dyslipidemia, smoking status, previous 
acute myocardial infarction, previous coronary artery bypass grafting, history of ischemic heart disease, previous percutaneous 
coronary intervention, previous cerebrovascular accidents, family history of coronary artery disease, bed size of hospital, 
region of hospital, location/teaching status of hospital, year of admission, history of cardiac arrest, ventricular tachycardia and 
ventricular fibrillation, atrial fibrillation, acquired immune deficiency syndrome, rheumatoid arthritis/collagen vascular 
diseases, congestive heart failure, chronic pulmonary disease, coagulopathy, diabetes, hypertension, hypothyroidism, liver 
disease, lymphoma, metastatic cancer, other neurological disorders, obesity, peripheral vascular disorders, solid tumor without 
metastasis, valvular heart disease, and weight loss.  
 
 
Table 1. In-hospital clinical outcomes of total cohort according to frailty risk group 

























MACE, %* 3.5 9.9 13.9 5.0 <0.001 
All-cause mortality, % 0.4 2.9 5.3 1.0 <0.001 
Procedure-related bleeding, % 2.0 6.0 8.7 2.9 <0.001 
Thoracic complications, % 2.3 5.2 7.5 3.0 <0.001 
Pneumothorax, % 1.7 4.4 6.7 2.3 <0.001 
Hemothorax, % 0.0 0.0 0.1 0.0003 <0.001 
Hemopericardium, % 0.0 0.1 0.1 0.1 <0.001 
Cardiac tamponade, % 0.1 0.3 0.5 0.2 <0.001 
Cardiac complications, % 0.3 0.7 0.7 0.4 <0.001 
Device-related infection, %* 0.6 2.0 1.9 0.9 <0.001 
Lead revision, % 1.6 1.5 1.4 1.6 0.003 
Pocket revision, % 1.0 1.5 1.6 1.2 <0.001 
Length of stay (days), median (IQR) 3 (1,6) 8 (5,13) 11 (7,19) 4 (2,7) <0.001 




















Thoracic Complications Cardiac Complications 
 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) p-value 
Total  
LRF (reference) - - - - - - - - - - 
IRF 2.41 [2.38, 2.45] <0.001 5.01 [4.85, 5.18] <0.001 2.20 [2.16, 2.24] <0.001 1.76 [1.73, 1.79] <0.001 1.82 [1.74, 1.92] <0.001 
HRF 2.97 [2.87, 3.08] <0.001 8.32 [7.82, 8.84] <0.001 2.44 [2.33, 2.55] <0.001 2.01 [1.92, 2.11] <0.001 1.52 [1.32, 1.75] <0.001 
PPM 
LRF (reference) - - - - - - - - - - 
IRF 2.20 [2.17, 2.24] <0.001 4.67 [4.49, 4.85] <0.001 2.09 [2.05, 2.14] <0.001 1.64 [1.60, 1.67] <0.001 1.89 [1.77, 2.00] <0.001 
HRF 2.79 [2.67, 2.90] <0.001 8.18 [7.63, 8.77] <0.001 2.48 [2.35, 2.60] <0.001 1.93 [1.83, 2.04] <0.001 1.72 [1.47, 2.01] <0.001 
CRT-P 
LRF (reference) - - - - - - - - - - 
IRF 2.96 [2.74, 3.20] <0.001 4.81 [4.00, 5.78] <0.001 2.84 [2.54, 3.17] <0.001 2.16 [1.96, 2.38] <0.001 4.39 [3.33, 5.79] <0.001 
HRF 3.59 [2.96, 4.36] <0.001 8.57 [5.87, 12.50] <0.001 3.88 [3.03, 4.95] <0.001 2.24 [1.76, 2.86] <0.001 3.78 [1.81, 7.87] <0.001 
CRT-D 
LRF (reference) - - - - - - - - - - 
IRF 3.07 [2.95, 3.19] <0.001 6.83 [6.16, 7.58] <0.001 2.78 [2.61, 2.95] <0.001 2.08 [1.97, 2.19] <0.001 1.55 [1.32, 1.81] <0.001 
HRF 3.00 [2.62, 3.43] <0.001 7.06 [5.41, 9.21] <0.001 2.45 [2.02, 2.97] <0.001 1.67 [1.37, 2.03] <0.001 1.34 [0.77, 2.32] 0.303 
ICD 
LRF (reference) - - - - - - - - - - 
IRF 2.71 [2.62, 2.80] <0.001 5.97 [5.45, 6.54] <0.001 2.16 [2.06, 2.26] <0.001 1.95 [1.87, 2.04] <0.001 1.57 [1.41, 1.76] <0.001 
HRF 3.53 [3.21, 3.87] <0.001 9.07 [7.51, 10.95] <0.001 1.75 [1.53, 1.99] <0.001 2.54 [2.26, 2.87] <0.001 1.12 [0.98, 1.21] 0.07 
ICD: automated implantable cardioverter-defibrillator; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; PPM: permanent 
pacemaker; MACE: Composite of mortality, thoracic and cardiac complications, device-related infection and reoperation; HRF: High-risk frailty; IRF: Intermediate-risk frailty; 
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